Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-H2158 plus entecavir in chronic hepatitis B infection
2019-004902-85Phase 2Unknown
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in hepatitis B (HBV) comparing ABI-H2158 + entecavir with Placebo + entecavir (2 arms). Primary endpoint: Safety and tolerability of ABI-H2158 + entecavir. Status: unknown.
02
Drugs
firzacorvir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2019-004902-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004902-85.